Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C

被引：53

作者：

Greig, Sarah L. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2016年 / 76卷 / 16期

关键词：

DRUG-DRUG INTERACTION; PATIENT-REPORTED OUTCOMES; FIXED-DOSE COMBINATION; GENOTYPE; VIRUS-INFECTION; INTERACTION PROFILE; NS5A INHIBITOR; HCV; VELPATASVIR; SOFOSBUVIR;

D O I：

10.1007/s40265-016-0648-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

A once-daily, single-tablet, pangenotypic regimen comprising the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir and the HCV NS5A inhibitor velpatasvir (sofosbuvir/velpatasvir; Epclusa(A (R))) was recently approved for the treatment of adults with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in the USA, EU and Canada. In the phase III ASTRAL trials, once-daily oral sofosbuvir/velpatasvir for 12 weeks provided very high rates of sustained virological response at 12 weeks post treatment (SVR12) in treatment-naive and -experienced patients with chronic HCV genotype 1-6 infection, including those with compensated cirrhosis or HIV-1 co-infection. High SVR12 rates were also observed with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with chronic HCV genotype 1-6 infection and decompensated cirrhosis. Sofosbuvir/velpatasvir was generally well tolerated, with low rates of adverse events. Thus, sofosbuvir/velpatasvir represents a valuable treatment option in adults with chronic HCV genotype 1-6 infection, including those with compensated or decompensated cirrhosis, previous treatment experience or HIV-1 co-infection.

引用

页码：1567 / 1578

页数：12

共 38 条

[1] SOF/VEL FOR 12 WEEKS RESULTS IN HIGH SVR12 RATES IN SUBJECTS WITH NEGATIVE PREDICTORS OF RESPONSE TO TREATMENT: AN INTEGRATED ANALYSIS OF EFFICACY FROM THE ASTRAL-1, ASTRAL-2 AND ASTRAL-3 STUDIES [J].

Agarwal, K. ;

Patel, K. ;

Samuel, D. ;

Bourliere, M. ;

Younes, Z. ;

Morgan, T. ;

Strasser, S. ;

Leggett, B. ;

Liu, L. ;

Ding, X. ;

McNally, J. ;

Osinusi, A. ;

Brainard, D. ;

Subramanian, M. ;

Afdhal, N. .

JOURNAL OF HEPATOLOGY, 2016, 64 :S787-S788

[2] ON TREATMENT HCV RNA AS A PREDICTOR OF SVR12 IN PATIENTS WITH GENOTYPE 1-6 HCV INFECTION TREATED WITH SOFOSBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS: AN ANALYSIS OF THE ASTRAL-1, ASTRAL-2, AND ASTRAL-3 STUDIES [J].

Alqatani, S. ;

Zeuzem, S. ;

Bourgeois, S. ;

Mathurin, P. ;

Rojter, S. ;

Everson, G. ;

Abergel, A. ;

De Ledinghen, V. ;

Liu, L. ;

Ding, X. ;

Mcnally, J. ;

Osinusi, A. ;

Brainard, D. ;

Subramanian, M. ;

Mangia, A. ;

Sulkowski, M. .

JOURNAL OF HEPATOLOGY, 2016, 64 :S817-S817

[3]

[Anonymous], J HEPATOL S2

[4]

[Anonymous], 2016, RECOMMENDATIONS FOR

[5] Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives [J].

Asselah, Tarik ;

Boyer, Nathalie ;

Saadoun, David ;

Martinot-Peignoux, Michele ;

Marcellin, Patrick .

LIVER INTERNATIONAL, 2016, 36 :47-57

[6]

Brau N, 2016, INTERNATIONAL AIDS C

[7] Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis [J].

Curry, M. P. ;

O'Leary, J. G. ;

Bzowej, N. ;

Muir, A. J. ;

Korenblat, K. M. ;

Fenkel, J. M. ;

Reddy, K. R. ;

Lawitz, E. ;

Flamm, S. L. ;

Schiano, T. ;

Teperman, L. ;

Fontana, R. ;

Schiff, E. ;

Fried, M. ;

Doehle, B. ;

An, D. ;

McNally, J. ;

Osinusi, A. ;

Brainard, D. M. ;

McHutchison, J. G. ;

Brown, R. S., Jr. ;

Charlton, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) :2618-2628

[8] Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection A Randomized Trial [J].

Everson, Gregory T. ;

Towner, William J. ;

Davis, Mitchell N. ;

Wyles, David L. ;

Nahass, Ronald G. ;

Thuluvath, Paul J. ;

Etzkorn, Kyle ;

Hinestrosa, Federico ;

Tong, Myron ;

Rabinovitz, Mordechai ;

McNally, John ;

Brainard, Diana M. ;

Han, Lingling ;

Doehle, Brian ;

McHutchison, John G. ;

Morgan, Timothy ;

Chung, Raymond T. ;

Tran, Tram T. .

ANNALS OF INTERNAL MEDICINE, 2015, 163 (11) :818-+

[9] Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection [J].

Feld, J. J. ;

Jacobson, I. M. ;

Hezode, C. ;

Asselah, T. ;

Ruane, P. J. ;

Gruener, N. ;

Abergel, A. ;

Mangia, A. ;

Lai, C. -L. ;

Chan, H. L. Y. ;

Mazzotta, F. ;

Moreno, C. ;

Yoshida, E. ;

Shafran, S. D. ;

Towner, W. J. ;

Tran, T. T. ;

McNally, J. ;

Osinusi, A. ;

Svarovskaia, E. ;

Zhu, Y. ;

Brainard, D. M. ;

McHutchison, J. G. ;

Agarwal, K. ;

Zeuzem, S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) :2599-2607

[10] Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection [J].

Foster, G. R. ;

Afdhal, N. ;

Roberts, S. K. ;

Braeu, N. ;

Gane, E. J. ;

Pianko, S. ;

Lawitz, E. ;

Thompson, A. ;

Shiffman, M. L. ;

Cooper, C. ;

Towner, W. J. ;

Conway, B. ;

Ruane, P. ;

Bourliere, M. ;

Asselah, T. ;

Berg, T. ;

Zeuzem, S. ;

Rosenberg, W. ;

Agarwal, K. ;

Stedman, C. A. M. ;

Mo, H. ;

Dvory-Sobol, H. ;

Han, L. ;

Wang, J. ;

McNally, J. ;

Osinusi, A. ;

Brainard, D. M. ;

McHutchison, J. G. ;

Mazzotta, F. ;

Tran, T. T. ;

Gordon, S. C. ;

Patel, K. ;

Reau, N. ;

Mangia, A. ;

Sulkowski, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) :2608-2617

← 1 2 3 4 →